Evidence map›Paper›PMID 36915143›Full record

ArticleEuropean journal of medical research2023

The impact of lymphovascular space invasion on survival in early stage low-grade endometrioid endometrial cancer.

Fariba Yarandi, Elham Shirali, Setare Akhavan, Fatemeh Nili, Sara Ramhormozian

Open access · goldFull text read
In one paragraph

Article in European journal of medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. AKR1B1 and AKR1B10 as Potential Prognostic Biomarkers of Endometrial Cancer.International journal of molecular sciences · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Fariba YarandiDepartment of Gynecologic Oncology, Yas Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Elham ShiraliDepartment of Gynecologic Oncology, Yas Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Setare AkhavanDepartment of Gynecologic Oncology, Vali-Asr Hospital, Tehran University of Medical Sciences, Imam Khomeini Hospital Complex (IKHC), Tehran, Iran.
Fatemeh NiliDepartment of Pathology, Tehran University of Medical Sciences, Imam Khomeini Hospital Complex, Tehran, Iran.
Sara RamhormozianDepartment of Gynecologic Oncology, Yas Hospital, Tehran University of Medical Sciences, Tehran, Iran. Sara.ramhormozian@gmail.com.
Tehran University of Medical Sciences · IRImam Khomeini Hospital · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe lymphovascular space invasion (LVSI) is suggested as a prognostic factor for endometrial cancer in many studies, but it has not yet been employed in FIGO staging system. The present study was aimed to evaluate the impact of LVSI on survival in patients with early stage endometrioid endometrial cancer.

methodsThis retrospective cohort was conducted on early stage endometrial cancer patients who underwent surgical staging [total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH/BSO)] and omental biopsy at Referral Teaching Hospitals of Tehran from 2005 to 2021. Patient's age, menopause status, tumor grade, tumor size, depth of myometrial invasion, LVSI and lower segment involvement were recorded. Data were analyzed with SPSS 22.

results415 patients with stage I and grade 1-2, endometrioid endometrial cancer were analyzed. 100 patients (24.1%) were LVSI-positive. 3-year and 5-year survival rates were 97.1% and 88.9%, respectively. Recurrence occurred in 53 patients (12.8%). 3-year overall survival rates in LVSI-negative and LVSI-positive were 98.7% and 92%. These rates for 5-year survival were 92.1% and 79%, respectively. Recurrence rates in LVSI-negative were 8.9% while it was 25% in LVSI-positive cases. Multivariate analysis showed that LVSI has significant correlation with 3-year and 5-year overall survival rates.

conclusionsLVSI in early stage endometrial cancer significantly and independently influences 3-year and 5-year survival rates and acts as a strong prognostic factor in these patients. LVSI should be implemented in endometrial cancer staging systems due to its significant correlation with cancer recurrence rates and 5-year survival rates.

Indexed as

Carcinoma, EndometrioidEndometrial NeoplasmsFemaleHumansIranNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPrognosisRetrospective StudiesEndometrial cancerLow-grade endometrioid adenocarcinomaLVSIPrognostic factorStagingSurvival

Identifiers

PMID36915143
PMCPMC10012545
OpenAlexW4324130178

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read168
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.